Ethel Weld, MD

Protocol chair, IMPAACT 2005
Protocol vice-chair, IMPAACT 2022
Member, Clinical Pharmacology Advisory Group of the ACTG Laboratory Steering Committee (2018-Present)
Member, ACTG Antiretroviral Therapy Strategies Transformative Science Group Less Frequent Dosing ART Working Group
Member, Pharmacology Core, HPTN Laboratory Core
Member, TB in Pregnancy Working Group
Protocol pharmacologist for HPTN 086, IMPAACT CAP 544, IMPAACT CAP 543

TB is a major cause of illness and death in women of reproductive age. Pregnant and postpartum women with latent TB are at...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

The A5322 protocol is a long-term observational study, with a planned series of analyses of data to be collected from an...

Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...

Study Description A5384 is a trial for people who have or might have tuberculous meningitis (TBM). TBM is an infectious disease...

Johns Hopkins University Baltimore-India Clinical Trials Unit